Search

Your search for "vvos" returned the following results.
Filter Results:
InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Participate at H.C. Wainwright 23rd Annual Global Investment Conference

September 8, 2021

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild-to-moderate obstructive sleep apnea (“OSA”) and snoring, today announced its participation at the H.C. Wainwright 23rd Annual Global Investment Conference. Vivos CEO Kirk Huntsman will be presenting at the event beginning at 7:00 a.m. EDT on […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Partners with Empower Sleep in Effort to Improve OSA Diagnosis, Treatment

August 26, 2021

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), is teaming up with Empower Sleep. Vivos and the California-based company, which works to empowering patients with affordable, accessible and personalized telemedicine sleep care, are […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Receives FDA Clearance for mmRNA Oral Appliance

August 23, 2021

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), has received 510(k) market clearance from the FDA for its modified mandibular repositioning nighttime appliance (“mmRNA”). The device is designed to treat mild-to-moderate OSA in […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Detailed Summary of National Study

August 18, 2021

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), has released a detailed summary of the results from its most recent national study. Those results include the fact that one in four patients in […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q2 2021 Financial, Operational Report

August 13, 2021

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), has announced its most recent financial report, along with operational highlights for the second quarter, the period ended June 20, 2021. In part, the report […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Participation in Q3 Virtual Investor Summit

August 10, 2021

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), will participate in the upcoming two-day Q3 Virtual Investor Summit. Vivos CEO Kirk Huntsman along with CFO Brad Amman and Ed Loew, Vivos investor relations […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Conference Call to Discuss Q2 2021 Financial Results

August 9, 2021

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), has scheduled a conference call and live webcast for Aug. 12, 2021, to begin at 5 p.m. ET. The purpose of the call is to […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Opening of Denver-Based State-of-the-Art International Training Center

July 29, 2021

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), today announced that it has opened the Vivos Institute training center in Denver, Colorado. The 15,000-square-foot facility was established to provide advanced post-graduate education and […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Promising Study Results for Game-Changing Technology

July 13, 2021

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, today announced results from a national study it commissioned to asses patients’ airway function and obstructive sleep apnea (“OSA”) symptoms after undergoing the Vivos treatment. The study found that 28% of […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Unveils Study Data Showing 97% of Vivos Patients Report Reaching Desired Outcome

July 7, 2021

Vivos Therapeutics (NASDAQ: VVOS) has released data from an independent patient survey related to its proprietary Vivos treatment for dental tissue anomalies and dentofacial malformations associated with obstructive sleep apnea (“OSA”) and other debilitating health conditions. The study reported that approximately 97% of patients surveyed said that they had achieved their desired outcome from the […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc.’s (NASDAQ: VVOS) Strides in Treatment Innovation Highlighted in New Book

July 1, 2021

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, has been a trailblazer in diagnosing and treating mild-to-moderate obstructive sleep apnea (“OSA”). Years of research have culminated in its main product, the Vivos System, which has been instrumental in treating OSA among adults. […]

News Articles

Vivos Therapeutics Inc. (NASDAQ: VVOS) Founder and Chief Medical Officer Shares Company’s Groundbreaking Work in New Book

June 25, 2021

Dr. Dave Singh, Vivos Therapeutics Inc. founder and Chief Medical Officer, releases his new book titled Pneumopedics and Craniofacial Epigenetics The book is the product of Dr. Singh’s years of research and is a chronology of Vivo Therapeutics’ strides in innovation The book mainly covers craniofacial growth and developmental Genetics It also highlights the relationship […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) CEO Discusses Unique System That Rebuilds Human Airway on Relentless Dentist Podcast

June 9, 2021

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), was featured in a recent episode of the Relentless Dentist podcast. The program features interviews with thought-provoking guests offering words of wisdom to help dentists gain the courage […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Founder, CEO Authors Book Focused on Groundbreaking Work

May 26, 2021

Vivos Therapeutics (NASDAQ: VVOS) founder and chief medical officer, Dr. G. Dave Singh, DMD, PhD, DDSc, has written a new book with the intent of assisting doctors and dentists in better understanding how to address underlying craniofacial conditions that impact a patient’s overall airway, breathing and sleep health. Titled “Pneumopedics and Craniofacial Epigenetics,” the book covers craniofacial […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Appoints Widely Acclaimed Leader as New Medical Director of Clinical Education

April 14, 2021

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), today announced the appointment of Mimi Guarneri, MD, FACC as an independent consultant serving in the role of medical director of Clinical Education, effective April 1, 2021. Dr. […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Participation in Upcoming Emerging Growth Conference

April 12, 2021

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”), will be presenting at the Emerging Growth Conference this week. VVOS CEO Kirk Huntsman, along with chief financial officer Brad Amman and investor relations officer Ed Loew, will host […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Unveils New MyoCorrect Orofacial Myofunctional Therapy Service

March 30, 2021

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”), has announced a new service called MyoCorrect. The exclusive training provides therapists with access to orofacial myofunctional therapy (“OMT”) via telemedicine technology using the company’s Vivos System. Vivos anticipates this new […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q4, FY 2020 Financial, Operational Results

March 26, 2021

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”), reported is financial and operational results for the fourth quarter and fiscal year ending Dec. 31, 2020. The company also held a conference call on March 25, 2021, to […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Present at Benzinga Biotech Conference

March 23, 2021

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), has announced that it will participate at the Benzinga Biotech Small Cap Conference taking place from March 24-25, 2021. Vivos Chief Executive Officer, Kirk Huntsman, Chief Financial Officer, […]

News Articles

Vivos Therapeutics Inc. (NASDAQ: VVOS) Featured in Virtual Coverage of Investor Summit Group’s Q1 Virtual Summit

March 22, 2021

Vivos Therapeutics Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative treatments for adult patients suffering from sleep-disordered breathing, including obstructive sleep apnea (OSA). The Vivos treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. Vivos believes that its Vivos System technology represents the first […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Conference Call to Release, Discuss Q4, FY 2020 Financial Results

March 18, 2021

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”), plans to release its fourth-quarter and full-year financial reports on March 25, 2021, after market close; the numbers will cover the period ending Dec. 31, 2020. The company has […]

News Articles

Vivos Therapeutics Inc. (NASDAQ: VVOS) Featured in Virtual Coverage of the 33rd Annual ROTH Conference

March 16, 2021

Vivos Therapeutics Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative treatments for adult patients suffering from sleep-disordered breathing, including obstructive sleep apnea (OSA). The Vivos treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. Vivos believes that its Vivos System technology represents the first […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Leaders to Present at Upcoming Virtual Investor Summit

March 11, 2021

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”) has announced that CEO Kirk Huntsman, CFO Brad Amman and investor relations officer Ed Loew are scheduled to present at the Q1 Virtual Investor Summit. Vivos Therapeutics’ presentation is […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces FDA 510(k) Application for Exclusive Oral Appliance

March 10, 2021

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”), recently submitted an application to the U.S. Food and Drug Administration (“FDA”) for its mmRNA (“mmRNA”) oral appliance(TM). The 510(k) Class II application focuses on the oral appliance as […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Opens First-Ever Pneusomnia Clinic, Unveils New Tech to Test for Sleep Apnea at Home

March 8, 2021

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”), has opened the first Pneusomnia clinic, a clinician-owned, integrated medical-dental sleep center. The center will feature the Vivos System through its Medical Integration Division. Located in Del Mar, California, the clinic is […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Establishes Clinical Advisory Board to Help Drive Growth

March 5, 2021

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”), announced the creation of its new Clinical Advisory Board. The six-member board will focus on driving adoption and growth of Vivos’ next-gen treatments for OSA. Reports indicate that an […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Secures $24.2M in Initial Public Offering

February 10, 2021

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company that offers novel and proprietary alternatives for treating mild-to-moderate obstructive sleep apnea, has closed its initial public offering of 4,025,000 shares of its common stock, including an additional 525,000 shares per the full exercise of the over-allotment option granted to the underwriters. According to the update, Vivos […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Launches Proprietary Technology for Obstructive Sleep Apnea Treatment

January 6, 2021

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep disordered breathing, including obstructive sleep apnea, announced its commercial launch of AireO2(TM). AireO2 is a new patient-management software technology designed to assist health-care providers to diagnose, treat and monitor patients with obstructive sleep apnea (“OSA”) […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Closes IPO, Exercises Option to Purchase Additional Shares

December 16, 2020

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep disordered breathing, including obstructive sleep apnea, has announced the closing of its initial public offering (“IPO”). The IPO consisted of a total of 4,025,000 shares — 3,500,000 shares of common stock combined with 525,000 additional shares […]

Press Releases

InvestorBrandNetwork Announces Relentless Dentist Podcast Featuring Vivos Therapeutics Inc. CEO R. Kirk Huntsman

June 9, 2021

LOS ANGELES, June 09, 2021 (GLOBE NEWSWIRE) — via InvestorWire — InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities, today announces that R. Kirk Huntsman, CEO and Director of Vivos Therapeutics Inc. (NASDAQ: VVOS), recently appeared on the Relentless Dentist, a podcast series featuring interviews with thought-provoking guests offering words of wisdom to help […]

News Articles

ROTH Announces Biotech / Medtech Details for Virtual 33rd Annual Roth Conference

March 15, 2021

ROTH is hosting its 33rd Annual Roth Conference virtually this year, from March 15-17. Featured at the event under the Pharmaceuticals/Medical technology umbrella will be 1-on-1/small group meetings for institutional investors, an industry panel and numerous virtual fireside chats. Details on the Panel: Flipping the Switch to Profitability Panel – March 16 at 10:00 AM […]

No ResultsNo content matches your search/filter.

 

 

 

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).